JP2023553533A5 - - Google Patents
Info
- Publication number
- JP2023553533A5 JP2023553533A5 JP2023560240A JP2023560240A JP2023553533A5 JP 2023553533 A5 JP2023553533 A5 JP 2023553533A5 JP 2023560240 A JP2023560240 A JP 2023560240A JP 2023560240 A JP2023560240 A JP 2023560240A JP 2023553533 A5 JP2023553533 A5 JP 2023553533A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124663P | 2020-12-11 | 2020-12-11 | |
| US202063124667P | 2020-12-11 | 2020-12-11 | |
| US202063124671P | 2020-12-11 | 2020-12-11 | |
| US202063124674P | 2020-12-11 | 2020-12-11 | |
| US63/124,674 | 2020-12-11 | ||
| US63/124,667 | 2020-12-11 | ||
| US63/124,663 | 2020-12-11 | ||
| US63/124,671 | 2020-12-11 | ||
| PCT/US2021/062921 WO2022125967A2 (en) | 2020-12-11 | 2021-12-10 | Combination therapies for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023553533A JP2023553533A (ja) | 2023-12-21 |
| JPWO2022125967A5 JPWO2022125967A5 (https=) | 2024-12-17 |
| JP2023553533A5 true JP2023553533A5 (https=) | 2024-12-17 |
Family
ID=81974875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560240A Pending JP2023553533A (ja) | 2020-12-11 | 2021-12-10 | 癌の処置のための併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240058352A1 (https=) |
| EP (1) | EP4259638A4 (https=) |
| JP (1) | JP2023553533A (https=) |
| KR (1) | KR20230152652A (https=) |
| AU (1) | AU2021396397A1 (https=) |
| CA (1) | CA3201654A1 (https=) |
| WO (1) | WO2022125967A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022125971A1 (en) * | 2020-12-11 | 2022-06-16 | Erasca, Inc. | Combination therapies for the treatment of cancer |
| US20240285624A1 (en) * | 2021-06-24 | 2024-08-29 | Erasca, Inc. | Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy |
| WO2023059771A1 (en) * | 2021-10-06 | 2023-04-13 | Erasca, Inc. | Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| TW202440128A (zh) * | 2023-01-06 | 2024-10-16 | 美商艾瑞斯卡公司 | Raf抑制劑及erk1/2及/或shp2抑制劑組合療法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016341445B2 (en) * | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| CA3074690A1 (en) * | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| JP7542538B2 (ja) * | 2018-09-18 | 2024-08-30 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体 |
| PH12021551949A1 (en) * | 2019-02-12 | 2022-07-18 | Janssen Pharmaceutica Nv | Cancer treatment |
-
2021
- 2021-12-10 JP JP2023560240A patent/JP2023553533A/ja active Pending
- 2021-12-10 CA CA3201654A patent/CA3201654A1/en active Pending
- 2021-12-10 WO PCT/US2021/062921 patent/WO2022125967A2/en not_active Ceased
- 2021-12-10 KR KR1020237023401A patent/KR20230152652A/ko not_active Abandoned
- 2021-12-10 AU AU2021396397A patent/AU2021396397A1/en not_active Abandoned
- 2021-12-10 EP EP21904512.7A patent/EP4259638A4/en not_active Withdrawn
- 2021-12-10 US US18/256,090 patent/US20240058352A1/en active Pending